These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35363198)

  • 21. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis.
    Taxonera C; Olivares D; López-García ON; Alba C
    Aliment Pharmacol Ther; 2023 Mar; 57(6):610-619. PubMed ID: 36645145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
    Chaparro M; Garre A; Iborra M; Sierra-Ausín M; Barreiro-de Acosta M; Fernández-Clotet A; de Castro L; Boscá-Watts M; Casanova MJ; López-García A; Lorente R; Rodríguez C; Carbajo AY; Arroyo MT; Gutiérrez A; Hinojosa J; Martínez-Pérez T; Villoria A; Bermejo F; Busquets D; Camps B; Cañete F; Manceñido N; Monfort D; Navarro-Llavat M; Pérez-Calle JL; Ramos L; Rivero M; Angueira T; Camo Monterde P; Carpio D; García-de-la-Filia I; González-Muñoza C; Hernández L; Huguet JM; Morales VJ; Sicilia B; Vega P; Vera I; Zabana Y; Nos P; Suárez Álvarez P; Calviño-Suárez C; Ricart E; Hernández V; Mínguez M; Márquez L; Hervías Cruz D; Rubio Iturria S; Barrio J; Gargallo-Puyuelo C; Francés R; Hinojosa E; Del Moral M; Calvet X; Algaba A; Aldeguer X; Guardiola J; Mañosa M; Pajares R; Piqueras M; García-Bosch O; López Serrano P; Castro B; Lucendo AJ; Montoro M; Castro Ortiz E; Mesonero F; García-Planella E; Fuentes DA; Bort I; Delgado-Guillena P; Arias L; Iglesias A; Calvo M; Esteve M; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Nov; 15(11):1846-1851. PubMed ID: 33860795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.
    Dalal RS; Esckilsen S; Barnes EL; Pruce JC; Marcus J; Allegretti JR
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2399-2401.e4. PubMed ID: 33775893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
    Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Panaccione R; Danese S; Sandborn WJ; O'Brien CD; Zhou Y; Zhang H; Adedokun OJ; Tikhonov I; Targan S; Abreu MT; Hisamatsu T; Scherl EJ; Leong RW; Rowbotham DS; Arasaradnam RP; Sands BE; Marano C
    Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1658-1675. PubMed ID: 33086438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
    Olbjørn C; Rove JB; Jahnsen J
    Paediatr Drugs; 2020 Aug; 22(4):409-416. PubMed ID: 32378002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of pulse steroid therapy in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
    Nagata S; Shimizu T; Kudo T; Tomomasa T; Tajiri H; Yoden A; Kagimoto S; Tahara T; Ushijima K; Uchida K; Kobayashi A
    Digestion; 2010; 81(3):188-92. PubMed ID: 20090334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
    Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
    [No Abstract]   [Full Text] [Related]  

  • 31. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis.
    Fanjiang G; Russell GH; Katz AJ
    J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):312-7. PubMed ID: 17325550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis.
    Miyoshi J; Matsuura M; Hisamatsu T
    Expert Opin Drug Saf; 2022 Jan; 21(1):1-8. PubMed ID: 34511011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S; Murad MH; Fumery M; Dulai PS; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2179-2191.e6. PubMed ID: 31945470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis.
    Veyrard P; Pellet G; Laharie D; Nachury M; Juillerat P; Roblin X
    Clin Gastroenterol Hepatol; 2023 May; 21(5):1354-1355.e2. PubMed ID: 35307594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States.
    Hong SJ; Krugliak Cleveland N; Akiyama S; Zullow S; Yi Y; Shaffer SR; Malter LB; Axelrad JE; Chang S; Hudesman DP; Rubin DT
    Crohns Colitis 360; 2021 Jan; 3(1):otab002. PubMed ID: 36777067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rare case of ulcerative colitis exacerbated by VZV infection.
    Nishimura S; Yoshino T; Fujikawa Y; Watanabe M; Yazumi S
    Clin J Gastroenterol; 2015 Dec; 8(6):390-2. PubMed ID: 26552918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
    Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
    Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.